Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAWH Ascend Wellness	$0.32 -8.5%	$0.35	$0.27 ▼ $1.40	$64.85M	1.2	112,720 shs	97,851 shs
ATYR Atyr PHARMA	$3.27 +9.0%	$3.27	$1.42 ▼ $4.66	$291.04M	0.79	920,243 shs	1.52 million shs
IMMP Immutep	$2.03 +2.5%	$1.72	$1.32 ▼ $3.34	$296.46M	1.8	222,212 shs	104,484 shs
TSVT 2seventy bio	$5.00	$4.97	$2.29 ▼ $5.30	$266.15M	1.04	630,373 shs	N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAWH Ascend Wellness	0.00%	-14.35%	-0.97%	-24.55%	-75.43%
ATYR Atyr PHARMA	0.00%	-0.61%	+5.48%	-4.11%	+326,999,900.00%
IMMP Immutep	0.00%	+9.73%	+31.82%	+3.57%	-28.01%
TSVT 2seventy bio	0.00%	+0.20%	+0.40%	+96.85%	+2.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATYR Atyr PHARMA	2.7126 of 5 stars	3.6	1.0	0.0	0.0	3.2	3.3	0.6
IMMP Immutep	1.5827 of 5 stars	3.5	2.0	0.0	0.0	2.8	0.0	0.0
TSVT 2seventy bio	1.1764 of 5 stars	0.9	2.0	0.0	0.0	3.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAWH Ascend Wellness	4.00	Strong Buy	N/A	N/A
ATYR Atyr PHARMA	3.14	Buy	$18.60	468.81% Upside
IMMP Immutep	3.00	Buy	$7.00	244.83% Upside
TSVT 2seventy bio	1.80	Reduce	$4.25	-15.00% Downside

Current Analyst Ratings Breakdown

Latest AAWH, ATYR, IMMP, and TSVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/22/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/14/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/14/2025	TSVT 2seventy bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
3/11/2025	TSVT 2seventy bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/11/2025	TSVT 2seventy bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$9.00 ➝ $5.00
3/7/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
2/19/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
2/18/2025	ATYR Atyr PHARMA	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAWH Ascend Wellness	$518.59M	0.13	$0.05 per share	6.64	$0.69 per share	0.46
ATYR Atyr PHARMA	$235K	1,238.48	N/A	N/A	$1.54 per share	2.12
IMMP Immutep	$5.14M	57.68	N/A	N/A	$1.05 per share	1.93
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAWH Ascend Wellness	-$48.21M	-$0.40	N/A	N/A	N/A	-15.47%	-72.18%	-9.55%	N/A
ATYR Atyr PHARMA	-$50.39M	-$0.81	N/A	N/A	N/A	N/A	-79.44%	-59.16%	N/A
IMMP Immutep	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	N/A

Latest AAWH, ATYR, IMMP, and TSVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
IMMP Immutep	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAWH Ascend Wellness	2.61	1.47	0.80
ATYR Atyr PHARMA	0.02	5.41	5.41
IMMP Immutep	0.01	18.25	18.25
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAWH Ascend Wellness	17.32%
ATYR Atyr PHARMA	61.72%
IMMP Immutep	2.32%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
AAWH Ascend Wellness	22.38%
ATYR Atyr PHARMA	3.70%
IMMP Immutep	3.07%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAWH Ascend Wellness	2,300	204.63 million	166.44 million	Not Optionable
ATYR Atyr PHARMA	53	89.00 million	80.84 million	Optionable
IMMP Immutep	2,021	146.04 million	141.09 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

AAWH, ATYR, IMMP, and TSVT Headlines

Recent News About These Companies

Madison Avenue Partners LP Sells 1,983,327 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

May 16 at 8:02 AM | marketbeat.com

2seventy bio (NASDAQ:TSVT) Given "Sell (D-)" Rating at Weiss Ratings

May 12, 2025 | marketbeat.com

Weiss Ratings Reaffirms Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)

May 12, 2025 | americanbankingnews.com

Engine Capital Management LP Sells 585,977 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

May 11, 2025 | marketbeat.com

DAFNA Capital Management LLC Sells 200,777 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

May 10, 2025 | marketbeat.com

2seventy bio (TSVT) Projected to Post Quarterly Earnings on Wednesday

May 9, 2025 | marketbeat.com

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025 | businesswire.com

Susquehanna Fundamental Investments LLC Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT)

May 7, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Marshall Wace LLP

May 3, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Given Average Recommendation of "Hold" by Brokerages

May 1, 2025 | marketbeat.com

2seventy bio (NASDAQ:TSVT) Earns Sell (E+) Rating from Weiss Ratings

April 27, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Sees Significant Drop in Short Interest

April 21, 2025 | marketbeat.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAWH, ATYR, IMMP, and TSVT Company Descriptions

Ascend Wellness OTC:AAWH

$0.32 -0.03 (-8.46%)

As of 05/16/2025 03:57 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

Atyr PHARMA NASDAQ:ATYR

$3.27 +0.27 (+9.00%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$3.27 0.00 (-0.03%)

As of 05/16/2025 07:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Immutep NASDAQ:IMMP

$2.03 +0.05 (+2.53%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.05 +0.02 (+0.99%)

As of 05/16/2025 07:49 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)

As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time